查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1495990

药物传输市场 - 2024 年至 2029 年预测

Drug Delivery Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 132 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2022年给药市场的市场规模为8,352.17亿美元，预计预测期内复合年增长率为8.90%，2029年市场总合规模达15,169.44亿美元。

药物输送装置是用于控制和标靶释放药物的专用装置。儘管几个世纪以来药物一直在提供健康益处并延长寿命，但近几十年来药物的传递方式发生了变化。分子生物学策略可用于发现透过与药物非标靶的身体部位相互作用来耐受副作用的药物。药物传输系统可控制药物的释放量和到达目标的距离。

慢性病盛行率的增加、医疗诊断市场的成长、技术进步和新公司的推出正在推动市场成长。根据世界卫生组织 (WHO) 预测，到 2020 年，慢性病盛行率预计将增加 57%。

此外，由于冠状病毒大流行，多家製药公司对感染疾病治疗的需求激增，这是拉动药品输送需求的主要因素。

此外，人们对药物输送系统的认识不断提高也有助于市场成长。此外，药物输送市场的成长也受到医疗保健和政府资金增加等其他因素的影响。此外，需要使用药物输送系统的各种慢性疾病的出现已成为药物传输系统市场的主要驱动因素。然而，药物输送市场因药物召回和缺陷的增加而受到阻碍。

新兴经济体也具有很高的成长潜力，这应该会在预测期内提供利润丰厚的机会。许多药物和疫苗正在进行各种临床试验，预计在未来几个月和几年内根据治疗 COVID-19 的紧急使用授权指南向患者提供。疫苗正在大规模开发、製造和管理，导致预测期内对各种药物输送系统的需求增加。

市场驱动因素：

  • 生技药品需求的成长预计将推动药物输送市场的发展。

生技药品是治疗多种疾病和病症的尖端治疗方法。根据世界卫生组织（WHO）统计，每年约有4,100万人死于慢性病，其中约1,790万人死于心血管疾病，其次是癌症（900万人）、呼吸道疾病（390万人）和糖尿病（ 160万人）。此外，大约80%的慢性病死亡是由这四类人群造成的。老年人口的成长也意味着慢性病影响更多的人，增加了对生技药品的需求。 65 岁及以上人口将从 2019 年的十分之一 (9%) 增加到 2050 年的六分之一 (16%)（资料来源：世界卫生组织）。投资者也在推动整体市场的成长。

此外，在新加坡，诺华公司投资7亿美元建立生技药品中心，百时美施贵宝投资超过9亿美元在爱尔兰建设大型生技药品设施，并于2019年开幕。未来几年，由于生技药品市场的显着增长以及非专利药注射剂主要透过注射给药的事实，注射给药市场应该会进一步成长。

市场限制因素：

  • 针刺伤可能会阻碍药物输送市场的成长。

与注射给药相关的主要风险之一是针刺伤。根据 Pharma Jet 报道，美国每年报告 60 万至 80 万起针刺伤事件。美国职业安全与健康管理局 (OSHA) 估计，美国有 560 万名工人因针刺伤而面临接触血源性病原体的风险。此外，CDC 估计美国医院每年发生 385,000 起针刺伤。

此外，世卫组织发现，全世界医护人员中 34.7% 的B型肝炎病例、56.9% 的C型肝炎病例和 46.7% 的爱滋病毒/爱滋病病例与针刺伤有关。

主要进展：

  • 2023 年 2 月：爱尔兰研发公司 Innovation Zed 的 InsulCheck DOSE附加元件设备获得 CE 标誌，该设备可自动记录胰岛素笔用户的给药时间和剂量次数。这种不显眼的设备可以捕捉剂量、注射事件时间戳记、温度、连接/移除事件，并将资料即时传输到相容的显示装置。 SHL Medical 和 SHL Technologies 的联合开发也解决了注射笔设计中的相容性挑战。
  • 2023 年 1 月 - 法国 Biocorp 的 SoloSmart® 获得 FDA 批准，SoloSmart® 是赛诺菲抛弃式胰岛素笔的智慧帽。这是 Biocorp 的 Mallya 平台第二次获得 FDA 批准。 SoloSmart 连接您的 SoloStar® 胰岛素笔，自动记录关键治疗资讯并将其发送到您的数位应用程式。这使得医疗保健专业人员可以更轻鬆地在多次治疗期间追踪患者。 FDA 的批准加强了 BioCorp 在智慧笔市场的技术领先地位。 SoloSmart 将于 2020 年开始销售，是 Biocorp连网型解决方案组合的一部分。
  • 2022 年 9 月 - BD 推出用于疫苗生产的新一代玻璃预充式註射器 (PFS)，既可靠又有效率。 BD EffivaxTM 玻璃预充式註射器是与一家製药公司合作开发的，旨在满足疫苗生产的复杂需求。百强生物製药公司中有70% 依赖BD 的PFS 供应，这种新设计提高了填充/完成和容器的可靠性，降低了生产线停机风险，并降低了总拥有成本、製造能力，并提高了可用性。
  • 2022 年 9 月—生物製药公司 Corium 宣布了其每週一次的经皮製剂 ADLARITY 对老年痴呆症失智症的 1 期研究结果。在这项研究中，发现 ADLARITY 提供的药物暴露量与口服多奈哌齐相当，且消化器官系统不利事件较少。 FDA核准了ADLARITY 5 毫克/天或 10 毫克/天的配方，使其成为第一个也是唯一一个每週一次的贴剂，可透过皮肤持续输送固定剂量的多奈哌齐。
  • 2022 年 6 月 - 诺华收购 Kedalion Therapeutics 和 AcuStream(TM) 平台。 AcuStream(TM) 平台是一种局部眼科给药装置，专为某些局部眼科药物的精确剂量和给药而设计。不含防腐剂的电子机械有可能改善患者体验并促进准确剂量。诺华计划开发 AcuStream 技术，用于现有和未来的眼前治疗，包括 Xiidra®，一种用于治疗干眼症的First-in-Class处方笺LFA 1 拮抗剂。 Kedalion Therapeutics 已完成由诺华主导的B 轮资金筹措，并拥有收购该公司及其 AcuStream 技术的独家选择权。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行概述

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球药物输送市场：依类型

  • 介绍
  • 吸入给药
  • 注射给药
  • 鼻腔给药
  • 口服给药
  • 经皮给药

第六章全球药物传输市场：依技术分类

  • 介绍
  • 无针注射器
  • 药物输送贴片
  • 自动注射器
  • 其他的

第七章全球药物输送市场：依应用分类

  • 介绍
  • 癌症治疗
  • 感染疾病治疗
  • 其他的

第八章全球药物输送市场：按地区

  • 介绍
  • 北美洲
  • 南美洲
  • 欧洲
  • 中东/非洲
  • 亚太地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • Pfizer
  • Insulet Corporation
  • West Pharmaceutical Services, Inc.
  • Enable Injections
  • Mersana Therapeutics
  • Becton, Dickinson and Company
  • Recipharm AB
  • Medtronic
  • Boston Scientific Corporation
简介目录
Product Code: KSI061612100

The drug delivery market was valued at US$835.217 billion in 2022 and is expected to grow at a CAGR of 8.90% over the forecast period to reach a total market size of US$1,516.944 billion by 2029.

A drug delivery device is a specialized device for the controlled and targeted release of drugs. Drugs have been extending health benefits and lifespans for centuries, and the way medicines are delivered has changed over the last few decades. Molecular biology strategies can be used to discover a medication that has acceptable side effects due to interacting with parts of the body that are not targeted by the drug. Systems for delivering drugs control how much of the drug is released and how far it reaches the target.

Increasing incidences of chronic diseases, growth in the medical diagnostics market, advancements in technology, and new company launches are driving the market growth. Globally, chronic disease prevalence is expected to rise by 57% by 2020, according to the World Health Organization.

Additionally, several pharmaceutical companies are suddenly experiencing a surge in demand for drugs designed to treat infectious diseases because of the Coronavirus outbreak globally, which has been a major factor boosting the drug delivery demand.

The growing awareness surrounding pharmaceutical drug delivery systems is also contributing to the market growth. Furthermore, the pharmaceutical drug delivery market growth is being influenced by additional factors such as an increase in healthcare and government funding. In addition, the emergence of various chronic diseases, which necessitate the use of pharmaceutical delivery systems, is a key driver of the pharmaceutical delivery systems market. The drug delivery market is, however, hindered by the increasing number of drug recalls and failures.

Additionally, the forecast period should see lucrative opportunities in developing economies due to their high growth potential. A great number of drugs and vaccines are undergoing various clinical trials and are expected to be made available to patients in the coming months and years under guidelines for emergency usage authorizations for COVID-19 treatment. Vaccines are being developed, manufactured, and administered at a mass level, which is resulting in high demand for different drug delivery systems over the forecast period.

Market Drivers:

  • Growth in the biologics drug demand is anticipated to surge the drug delivery market.

Biologic drugs are the most advanced treatments available for a variety of illnesses and conditions. Approximately 41 million people die each year from chronic diseases, according to World Health Organization statistics, and about 17.9 million people die from cardiovascular disease, followed by cancer (9 million), respiratory diseases - 3.9 million, and diabetes - 1.6 million. Furthermore, approximately 80% of chronic disease deaths result from these four groups. The increasing number of geriatrics also means that chronic diseases will affect more people, thus increasing the demand for biologics. The number of people over the age of 65 will rise from one in 11 in 2019 to one in six by 2050 (16%), up from one in 11 at the beginning of this year (9%) (Source: WHO). Investors have also been driving the overall market growth.

Moreover, in Singapore, Novartis AG invested USD 700 million in the establishment of a biologics center, while Bristol-Myers Squibb spent more than USD 900 million on a large biologic facility in Ireland, which opened in 2019. In the coming years, due to the significant growth in the biologics market and the fact that generic injectables are mainly administered via injection, the injectable drug delivery market should witness further growth.

Market Restraint:

  • Injuries caused by needlesticks could hamper the drug delivery market growth.

One of the major risks associated with injectable drug delivery is needlestick injuries. According to Pharma Jet, 600,000-800,000 needlestick injuries are reported in the United States every year. The Occupational Safety and Health Administration (OSHA) estimates that 5.6 million workers in the US are at risk of being exposed to blood-borne pathogens because of needlestick injuries. In addition, the CDC estimates that US hospitals suffer 385,000 needlestick injuries annually.

In addition, the WHO found that 34.7% of cases of Hepatitis B, 56.9% of cases of Hepatitis C, and 46.7% of cases of HIV/AIDS among healthcare workers worldwide were associated with injuries caused by needlesticks.

Key Developments:

  • February 2023- Innovation Zed, an Irish R&D company, secured a CE Mark for the InsulCheck DOSE add-on device, which automatically logs the time and dialled doses for insulin pen users. The discreet device captures dose value, injection event time stamp, temperature, and mounting and unmounting events and sends real-time data to a compatible display device. It features a vibrant OLED screen for increased user engagement and was developed in collaboration with SHL Medical and SHL Technologies to address compatibility challenges in injection pen designs.
  • January 2023- Biocorp, a France-based company, received FDA clearance for SoloSmart(R), Sanofi's smart cap for disposable insulin pens. This marks the second FDA clearance for Biocorp's Mallya platform. SoloSmart connects SoloStar(R) insulin pens, automatically recording key treatment information and transmitting it to a digital application. It provides healthcare professionals with an easy way to follow patients during multitherapy treatments. The FDA's authorization reinforces Biocorp's technological leadership in the smart pens market. SoloSmart is available for sale from 2020 and is part of Biocorp's connected solutions portfolio.
  • September 2022- BD introduced a next-generation glass pre-fillable syringe (PFS) for vaccine manufacturing, designed for reliability and efficiency. The BD EffivaxTM Glass Prefillable Syringe, developed in collaboration with pharmaceutical companies, is designed to meet the complex needs of vaccine manufacturing. With 70% of the top 100 biopharmaceutical companies relying on BD for PFS supply, the new design enhances fill/finish and container reliability, reducing line stoppage risk and improving total cost of ownership, manufacturing capacity, and supply availability. BD is benefited from a $1.2 billion investment to expand and upgrade manufacturing capacity and technology for PFS.
  • September 2022- Corium, a biopharmaceutical company, published phase 1 results for ADLARITY, a once-weekly transdermal system for Alzheimer's dementia patients. The study found that ADLARITY delivered drug exposure equivalent to oral donepezil, with lower gastrointestinal adverse events. The FDA approved ADLARITY in 5 or 10 mg/day formulations, making it the first and only once-weekly patch to continuously deliver consistent doses of donepezil through the skin. The trial supports ADLARITY as a compliant and safe once-weekly dosing regimen for Alzheimer's dementia treatment.
  • June 2022- Novartis was acquired Kedalion Therapeutics and its AcuStream(TM) platform, a topical ocular delivery device designed for precise dosing and delivery of certain topical ophthalmic medications. The preservative-free, electromechanical device may improve patient experience and facilitate precise dosing. Novartis plans to develop AcuStream technology for use with existing and future front-of-eye therapies, including Xiidra(R), a first-in-class prescription LFA 1 antagonist for dry eye disease treatment. Kedalion Therapeutics completed its Series B financing led by Novartis, with an exclusive option to acquire the company and its AcuStream technology.

Market Segmentation:

By Type

  • Inhalation Drug Delivery
  • Injectable Drug Delivery
  • Nasal Drug Delivery
  • Oral Drug Delivery
  • Transdermal Drug Delivery

By Technique

  • Needle-free injectors
  • Drug delivery patches
  • Autoinjectors
  • Others

By Application

  • Cancer treatment
  • Infectious diseases treatment
  • Others

BY Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Japan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL DRUG DELIVERY MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Inhalation Drug Delivery
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Injectable Drug Delivery
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Nasal Drug Delivery
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Oral Drug Delivery
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness
  • 5.6. Transdermal Drug Delivery
    • 5.6.1. Market Opportunities and Trends
    • 5.6.2. Growth Prospects
    • 5.6.3. Geographic Lucrativeness

6. GLOBAL DRUG DELIVERY MARKET BY TECHNIQUE

  • 6.1. Introduction
  • 6.2. Needle-free injectors
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Drug delivery patches
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Autoinjectors
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Others
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness

7. GLOBAL DRUG DELIVERY MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Cancer treatment
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Infectious diseases treatment
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Others
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness

8. GLOBAL DRUG DELIVERY MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Technique
    • 8.2.3. By Application
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Technique
    • 8.3.3. By Application
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Technique
    • 8.4.3. By Application
    • 8.4.4. By Country
      • 8.4.4.1. Germany
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. France
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. United Kingdom
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Spain
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Others
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Technique
    • 8.5.3. By Application
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Israel
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
      • 8.5.4.4. Others
        • 8.5.4.4.1. Market Opportunities and Trends
        • 8.5.4.4.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Technique
    • 8.6.3. By Application
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. India
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. South Korea
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. Taiwan
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Thailand
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Indonesia
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Japan
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Pfizer
  • 10.2. Insulet Corporation
  • 10.3. West Pharmaceutical Services, Inc.
  • 10.4. Enable Injections
  • 10.5. Mersana Therapeutics
  • 10.6. Becton, Dickinson and Company
  • 10.7. Recipharm AB
  • 10.8. Medtronic
  • 10.9. Boston Scientific Corporation